RALLYBIO CORPORATION Income Tax Expense
RALLYBIO CORPORATION (RLYB) reported Income Tax Expense of $1.32 million for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-26
- RALLYBIO CORPORATION income tax expense (benefit) for the quarter ending 2026-06-30 was $1.32M.
- RALLYBIO CORPORATION income tax expense (benefit) for the quarter ending 2025-06-30 was $0.00.
- RALLYBIO CORPORATION income tax expense (benefit) for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION income tax expense (benefit) for the quarter ending 2021-09-30 was $0.00.
- RALLYBIO CORPORATION income tax expense (benefit) for fiscal 2023 was $0.00.
- RALLYBIO CORPORATION income tax expense (benefit) for fiscal 2022 was $0.00.
- RALLYBIO CORPORATION income tax expense (benefit) for fiscal 2021 was $0.00.
- RALLYBIO CORPORATION income tax expense (benefit) for fiscal 2020 was -$15.00K.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.32M S-4/A · filed 2026-08-26 | $1.32M S-4/A · filed 2026-08-26 | ||
| 2025-12-31 | $0.00 S-4/A · filed 2026-08-26 | |||
| 2025-06-30 | $0.00 S-4/A · filed 2026-08-26 | $0.00 S-4/A · filed 2026-08-26 | ||
| 2024-12-31 | $0.00 S-4/A · filed 2026-08-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-12 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-09-09 | $0.00 10-Q · filed 2021-09-09 | ||
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $1.00K derived: sum of 2 quarters · filed 2022-03-15 | $1.00K derived: sum of 3 quarters · filed 2022-03-15 | -$15.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | -$16.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-09-09 | -$16.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |